Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
Holding BLUE?
Track your performance easily
BLUE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.56 - $5.53
Previous Close$0.56
Volume10.53M
Average Volume (3M)7.14M
Market Cap
$114.18M
Enterprise Value$243.59M
Total Cash (Recent Filing)$174.29M
Total Debt (Recent Filing)$303.71M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Nov 05, 2024EPS Estimate
-$0.38Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding109,336,211
10 Day Avg. Volume9,036,724
30 Day Avg. Volume7,137,446
Standard Deviation0.21
R-Squared0.04
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.31
Price to Sales (P/S)2.98
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.82
Enterprise Value/Gross Profit-37.59
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$4.17Price Target Upside642.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bluebird Bio News
PremiumCompany Announcements
Bluebird Bio Works to Resolve Financial Reporting Delays
Bulls Say, Bears Say
Bulls Say
Coverage And RevenueProgress in securing coverage for Lyfgenia with half of Medicaid sickle cell patients in states affirming coverage.
Manufacturing CapacityApproval to expand manufacturing capacity at Lonza facility will double production for Zynteglo and Skysona.
Patient DemandEarly indicators show robust demand for bluebird's therapies, suggesting current valuation underestimates potential.
Bears Say
Financial PerformanceThe company's $16.1M in 2Q revenues were below Street expectations of $24M.
FinancingRevised terms under the Hercules loan agreement introduced new capital raising requirements to remain eligible for the additional $25M debt tranches.
Sales ForecastSales forecasts for FY24-‘25 have been decreased and the peak sales estimate for Lyfgenia has notably been lowered to $730m from $970m.
---
Ownership Overview
4.95% Insiders
15.42% Mutual Funds
16.68% Other Institutional Investors
62.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLUE FAQ
What was bluebird bio’s price range in the past 12 months?
bluebird bio lowest stock price was $0.56 and its highest was $5.53 in the past 12 months.
What is bluebird bio’s market cap?
Currently, no data Available
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is Nov 05, 2024 which is in 66 days.
How were bluebird bio’s earnings last quarter?
bluebird bio released its earnings results on Aug 14, 2024. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.007.
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $8.88 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate is -$0.38.
How many shares outstanding does bluebird bio have?
bluebird bio has 192,741,940 shares outstanding.
What happened to bluebird bio’s price movement after its last earnings report?
bluebird bio reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went down -23.585%.
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Woodline Partners LP. It holds bluebird bio’s shares valued at 954K.
---
Bluebird Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.17 (642.65% Upside)
$4.17 (642.65% Upside)
Blogger Sentiment
Bullish
BLUE Sentiment 81%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 9.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
BLUE Earnings Call
Q2 2024
0:00 / 0:00
---
BLUE Stock 12 Month Forecast
Average Price Target
$4.17
▲(642.65% Upside)
Technical Analysis
Best Analysts Covering BLUE
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+12.19%
reiterated a sell rating 4 months ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +12.19% per trade.
---